Cellectis initiated at Goldman Sachs

Cellectis initiated with a Neutral at Goldman Sachs. Goldman Sachs analyst Salveen Richter started Cellectis with a Neutral rating and $25 price target. The analyst says it is time for the company to execute on its gene editing platform technology and prefers to remain on the sidelines pending clinical data readouts in 2019.
https://thefly.com/landingPageNews.php?id=2838981